title: Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
authors.affiliation: Gastroenterology Unit, Hospital Universitario de La Princesa, IIS-IP and CIBEREHD, Madrid, Spain. javier.p.gisbert@gmail.com.
authors.forename: J P
authors.initials: JP
authors.lastname: Gisbert
authors.affiliation: Gastroenterology Unit, Hospital Universitario de La Princesa, IIS-IP and CIBEREHD, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Chaparro
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols